Who should not rely on BPC-157 for alcohol protection: Anyone with diagnosed liver disease (cirrhosis, hepatitis, fatty liver disease) People with alcohol use disorder who need medical treatment, not peptide supplementation Anyone taking hepatotoxic medications (acetaminophen at high doses, certain statins, methotrexate) Individuals with bleeding disorders or on anticoagulants BPC-157 is not a substitute for medical care
"As a physician, I have to make sure that I'm keeping patients as safe as possible," panel member Dr
The mechanistic and preclinical evidence sits with the individual peptides chiefly GHK-Cu, which has the deepest literature while the specific three-peptide combination is used in research settings without combination-level trial data
bremelanotide) , has been described as a promising way to treat [hypoactive sexual desire disorder],46 a condition characterized by a chronic lack of sexual desire.47 PT-141 is available as a women-only prescription under the brand name Vyleesi, clinical trials for which have shown the drug to both improve sexual desire and decrease feelings of associated distress.48 PT-141 has also been tested in men, as in a 2005 study that coadministered the peptide with sildenafil to subjects with ED who either had not responded to or could not tolerate single-therapy treatment
